Superworth

Fortress Biotech profit margin FBIO

Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.

Net margin, 12 months
n/m
a quarter missing
Peer median
13.6%

Fortress Biotech's net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.

Profit margin over time

GrossNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginGross margin
FY2025n/an/a
FY2024−79.8%68.0%
FY2023−71.7%68.5%
FY2022n/a59.4%
FY2021−94.1%53.4%
FY2020n/a68.0%
FY2019n/a71.2%
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a
FY2015n/an/a
FY2014n/an/a
FY2013n/an/a
FY2012n/an/a
FY2011n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a year
Q2 FY26n/an/a
Q1 FY26n/an/a
Q4 FY25n/an/a
Q3 FY256.4%+84.0 pts
Q2 FY25−24.8%+24.4 pts
Q1 FY25−71.2%−7.2 pts
Q4 FY24−79.8%−8.0 pts
Q3 FY24−77.6%+19.1 pts
Q2 FY24−49.2%n/a
Q1 FY24−64.1%n/a
Q4 FY23−71.7%n/a
Q3 FY23−96.7%n/a

Against its peers

Companies in Drug Manufacturers - General nearest Fortress Biotech's size, closest first, today.

CompanyProfit margin
FBIOFortress Biotechn/m
SPROSpero Therapeutics15.7%
LFVNLifevantage2.8%
ATNMActinium Pharmaceuticalsn/m
NATRNatures Sunshine Products3.7%
ARVNArvinas2.9%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
CRMDCorMedix40.5%
Peer median13.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Fortress Biotech

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.